Waiv, formerly Owkin Dx, an artificial intelligence technology company dedicated to the development of precision oncology tests, has announced the closing of its $35 million funding round. The Series A round has been completed with an investment from CRB Digital Health III, the largest venture capital fund in Southern Europe exclusively dedicated to digital health, managed by CRB Health Tech.
These investors join OTB Ventures and Alpha Intelligence Capital, which co-led the initial round with the participation of Serena Data Ventures, Karista, and SistaFund, as announced in March 2026.
“Waiv is building one of the most promising platforms we have seen at the intersection of artificial intelligence and precision oncology. Its ability to extract molecular-grade insights from routine pathology has the potential to redefine how diagnostic services are delivered at scale. Our participation in this extension reflects our strong conviction both in the team, led by Meriem Sefta and Lionel Guillou, and in the long-term impact of their technology,” said Ignasi Heras Vila, General Partner at CRB Health Tech.
“This additional investment is a clear vote of confidence in what we are building at Waiv,” said Meriem Sefta, CEO and co-founder of Waiv. “With recent regulatory approvals secured and our platform already deployed in clinical settings, this capital will allow us to move even faster—expanding our presence across more laboratories, strengthening our commercial traction, and ultimately improving oncology and precision medicine care for more patients.”
This announcement follows a major regulatory milestone disclosed last week: Waiv has obtained CE marking under the IVDR for two of its AI-powered precision tests, RlapsRisk® BC, for prognostic risk profiling in breast cancer, and MSIntuit® CRC, for MSI screening in colorectal cancer. Together, these milestones place Waiv in an optimal position to accelerate adoption by laboratories and healthcare providers across Europe and beyond.
About Waiv
Waiv exists to catalyze precision medicine through clinical-grade AI-powered tests that accelerate biomarker detection, outcome prediction, and treatment response assessment in oncology. Built on more than seven years of validated innovation in medical AI and one of Europe’s largest multi-institutional data networks, Waiv delivers precise, accurate, and fast analyses that support therapeutic decision-making. Waiv partners with global pharmaceutical companies, research institutions, diagnostic organizations, and healthcare systems to bring scalable precision medicine to patients worldwide. For more information, visit https://wearewaiv.com/
About CRB Health Tech
CRB Health Tech is an independent venture capital firm founded in 2008, with offices in Madrid and Barcelona. CRB Digital Health III, its third fund, is the largest fund in Southern Europe exclusively focused on digital health. The fund invests in disruptive technologies in prevention, diagnosis, and treatment, as well as platforms that improve the efficiency and sustainability of healthcare systems, focusing on companies with validated business models and clear scalability potential.
For more information, visithttps://crbhealthtech.com/
cloud technology axon
The building, for which planning permission has already been granted, ...
